Ikena Oncology, Inc.

NasdaqGM:IKNA Stock Report

Market Cap: US$74.8m

Ikena Oncology Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Mark Manfredi

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage45.9%
CEO tenure7yrs
CEO ownershipn/a
Management average tenure1.2yrs
Board average tenure4.1yrs

Recent management updates

Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Jun 01
Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Recent updates

Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Jun 01
Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Growth Investors: Industry Analysts Just Upgraded Their Ikena Oncology, Inc. (NASDAQ:IKNA) Revenue Forecasts By 31%

Nov 10
Growth Investors: Industry Analysts Just Upgraded Their Ikena Oncology, Inc. (NASDAQ:IKNA) Revenue Forecasts By 31%

Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers

Aug 15
Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers

Need To Know: Analysts Are Much More Bullish On Ikena Oncology, Inc. (NASDAQ:IKNA) Revenues

May 20
Need To Know: Analysts Are Much More Bullish On Ikena Oncology, Inc. (NASDAQ:IKNA) Revenues

Will Ikena Oncology (NASDAQ:IKNA) Spend Its Cash Wisely?

Apr 29
Will Ikena Oncology (NASDAQ:IKNA) Spend Its Cash Wisely?

We Think Ikena Oncology (NASDAQ:IKNA) Needs To Drive Business Growth Carefully

Jan 06
We Think Ikena Oncology (NASDAQ:IKNA) Needs To Drive Business Growth Carefully

Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth

Aug 06
Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth

Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts

Mar 23
Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts

Ikena Oncology, Inc. (NASDAQ:IKNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 21
Ikena Oncology, Inc. (NASDAQ:IKNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Is Ikena Oncology (NASDAQ:IKNA) In A Good Position To Deliver On Growth Plans?

Feb 19
Is Ikena Oncology (NASDAQ:IKNA) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Rate

Nov 02
We're Not Very Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Rate

Ikena Oncology (NASDAQ:IKNA) Is In A Good Position To Deliver On Growth Plans

Jul 13
Ikena Oncology (NASDAQ:IKNA) Is In A Good Position To Deliver On Growth Plans

CEO Compensation Analysis

How has Mark Manfredi's remuneration changed compared to Ikena Oncology's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$60m

Jun 30 2024n/an/a

-US$67m

Mar 31 2024n/an/a

-US$70m

Dec 31 2023US$1mUS$569k

-US$68m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$63m

Mar 31 2023n/an/a

-US$66m

Dec 31 2022US$2mUS$546k

-US$69m

Sep 30 2022n/an/a

-US$52m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$41m

Dec 31 2021US$5mUS$530k

-US$34m

Sep 30 2021n/an/a

-US$63m

Jun 30 2021n/an/a

-US$55m

Mar 31 2021n/an/a

-US$47m

Dec 31 2020US$606kUS$410k

-US$44m

Compensation vs Market: Mark's total compensation ($USD1.24M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.

CEO

Mark Manfredi (53 yo)

7yrs

Tenure

US$1,240,640

Compensation

Dr. Mark Manfredi, Ph D., serves as Member of Scientific Advisory Board of Bantam Pharmaceutical, LLC. He has been President, Chief Executive Officer and Director of Ikena Oncology, Inc. since December 201...

Leadership Team

NamePositionTenureCompensationOwnership
Mark Manfredi
President7yrsUS$1.24mno data
Jotin Marango
CFO & Head of Corporate Development2.7yrsUS$782.32k0%
$ 0
Rebecca Cohen
Vice President of Investor Relationsless than a yearno datano data
Jeffrey Ecsedy
Chief Development Officer3.1yrsno datano data
Bob Lally
Senior Vice President of Finance & Operationsno datano datano data
David Damphousse
Senior Vice President of Clinical Development Operations1.2yrsno datano data
Caroline Germa
Chief Medical Officerless than a yearno datano data
Valdas Jurkauskas
Senior Vice President of Technical Operationsless than a yearno datano data

1.2yrs

Average Tenure

52.5yo

Average Age

Experienced Management: IKNA's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Mark Manfredi
President7yrsUS$1.24mno data
Jean-Francois Formela
Independent Director8.8yrsUS$130.36k0%
$ 0
George Demetri
Chair of Scientific Advisory Board4.1yrsno datano data
Otello Stampacchia
Independent Director4yrsUS$128.25k0%
$ 0
Neal Rosen
Member of Scientific Advisory Boardno datano datano data
Kevan Shokat
Member of Scientific Advisory Board4.1yrsno datano data
Owen Hughes
Chairman of the Board1.9yrsUS$167.86k0%
$ 0
David Bonita
Independent Director8.8yrsUS$131.86k0%
$ 0
Iain Dukes
Independent Director8.1yrsUS$126.97k0%
$ 0
Richard Wooster
Independent Director2.9yrsUS$117.86k0%
$ 0
Josep Tabernero Caturla
Member of Scientific Advisory Board4.1yrsno datano data
Maria Koehler
Independent Director3.7yrsUS$117.86k0%
$ 0

4.1yrs

Average Tenure

62.5yo

Average Age

Experienced Board: IKNA's board of directors are considered experienced (4.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:44
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ikena Oncology, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Evan SeigermanCredit Suisse
Judah FrommerCredit Suisse
Robert BurnsH.C. Wainwright & Co.